Channels - Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia :: FRELIP Discovery

Similar Items: Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia

Quick Look
Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study
Quick Look
Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults
Quick Look
Acute lymphoblastic leukemia in adolescents and young adults – from genomics to the clinics
Quick Look
Thyroid profile in acute lymphoblastic leukemia: prognostic role of thyrotropin-releasing hormone
Quick Look
Community Experience With Pediatric‐Inspired Regimens for Acute Lymphoblastic Leukemia in Adolescent and Young Adults
Quick Look
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study
Quick Look
Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy
Quick Look
Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia
Quick Look
Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort
Quick Look
Factors Associated With Alcohol Intake in Patients With Newly Diagnosed Breast Cancer
Quick Look
TNFAIP3 Reprograms T Cell Exhaustion and Restores Anti-Leukemia Immunity in Acute Myeloid Leukemia
Quick Look
Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia
Quick Look
Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
Quick Look
Aging Is a Key Driver for Adult Acute Myeloid Leukemia
Quick Look
Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia
Quick Look
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma
Quick Look
Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia
Quick Look
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study
Quick Look
Construction and Validation of an N7-Methylguanosine–Related Prognostic Model for Acute Myeloid Leukemia
Quick Look
Early assessment of endocan level as a predictor of remission status in acute leukemia patients
Quick Look
Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study
Quick Look
Gain and Loss of Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO)
Quick Look
Association of the PD‐L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer
Quick Look
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia